Supernus Pharmaceuticals Inc  

(Public, NASDAQ:SUPN)   Watch this stock  
Find more results for SUPN
+0.45 (1.15%)
After Hours: 39.50 0.00 (0.00%)
Nov 24, 1:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.80 - 39.75
52 week 20.55 - 50.04
Open 39.25
Vol / Avg. 117,822.00/477,661.00
Mkt cap 2.02B
P/E 35.99
Div/yield     -
EPS 1.10
Shares 51.26M
Beta 1.30
Inst. own 100%
Nov 29, 2017
Supernus Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - 8:00AM EST - Add to calendar
Nov 16, 2017
Supernus Pharmaceuticals Inc at Jefferies Global Healthcare Conference
Nov 14, 2017
Supernus Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 7, 2017
Q3 2017 Supernus Pharmaceuticals Inc Earnings Call - Webcast
Nov 6, 2017
Q3 2017 Supernus Pharmaceuticals Inc Earnings Release
Sep 26, 2017
Supernus Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 18, 2017
Supernus Pharmaceuticals Inc Announces Outcome of Interim Analysis from Phase III Clinical Trial on SPN-810 - Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 19.85% 42.43%
Operating margin 27.68% 24.90%
EBITD margin - 26.33%
Return on average assets 17.50% 36.62%
Return on average equity 26.62% 65.21%
Employees 363 -
CDP Score - -


1550 E Gude Dr
ROCKVILLE, MD 20850-1339
United States - Map
+1-301-8382500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Officers and directors

Charles W. Newhall III Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jack A. Khattar President, Chief Executive Officer, Secretary, Director
Age: 55
Bio & Compensation  - Reuters
Gregory S. Patrick Chief Financial Officer, Vice President
Age: 65
Bio & Compensation  - Reuters
Stefan K. F. Schwabe M.D. Ph.D. Executive Vice-President - Research and Development, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
Padmanabh P. Bhatt Ph.D. Senior Vice President - Intellectual Property, Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Victor Vaughn Senior Vice President - Sales and Marketing
Age: 59
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 71
Bio & Compensation  - Reuters
William A. Nuerge Independent Director
Age: 64
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters